Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17431389 | 0.85 | MEN1 (0.40) | PARP1NOS3NOS2TKT | |
| SCHEMBL7150826 | 0.85 | NOS3 (0.37) | NOS3NOS2ELANETP53 | |
| SCHEMBL21414452 | 0.78 | — | — | |
| SCHEMBL10730430 | 0.78 | NOS3 (0.46) | PARP1NOS3NOS2ELANETKT | |
| SCHEMBL7573152 | 0.78 | CCR1 (0.40) | GRM1 | |
| SCHEMBL30585580 | 0.78 | CCR1 (0.40) | GRM1 | |
| SCHEMBL7118882 | 0.76 | PSMB5 (0.38) | PARP1NOS3NOS2ELANETKT | |
| SCHEMBL25907277 | 0.76 | ALDH1A1 (0.37) | PARP1NOS3NOS2ELANEGAA | |
| SCHEMBL19242233 | 0.75 | ELANE (0.36) | PARP1ELANEGABRA1GABRB2CTRC | |
| SCHEMBL21604163 | 0.74 | NOS3 (0.42) | PARP1NOS3NOS2TKTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106854207-A | Dai piperazine analog derivative, its preparation method, pharmaceutical composition and purposes | 上海赛默罗生物科技有限公司 | 2017-06-16 | — | — | CN | disclosed |
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-04-03 | — | — | US | disclosed |
| US-4871848-A | OIL, GAS WELLS CORROSION INHIBITORS | THE DOW CHEMICAL COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| US-4740320-A | REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4725373-A | CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-02-16 | — | — | US | disclosed |
| US-4724003-A | Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines | THE DOW CHEMICAL COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4676834-A | Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone | THE DOW CHEMICAL COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | MYH10, MYLK, MKI67 | PARP1 866/4885NOS3 416/4885NOS2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.